Letter | Published:

Host genotype influences immunomodulation by interferon


Interferon influences both afferent and efferent pathways of delayed-type hypersensitivity (DH) in the mouse. In animals previously sensitised to picryl chloride, sheep red blood cells (SRBC) or Newcastle disease virus (NDV), and treated with interferon just before challenge with any of these antigens, the antigen-elicited reaction, as measured by the ear-swelling (picryl chloride) or footpad swelling (SRBC and NDV) test, is either decreased or completely inhibited, depending on the dose of interferon administered1,2. In addition to this action on expression of the sensitised state, interferon decreases or inhibits sensitisation to SRBC or NDV when administered 24 h before immunisation2,3. These effects were recently confirmed using electrophoretically pure mouse interferon, thus ruling out the possibility that they are caused by other proteins present in the previously used partially purified interferon preparations4. For the effect on sensitisation, the timing of interferon administration is crucial, and when interferon is administered a few hours after the antigen, sensitisation can actually be enhanced, as reported here; the enhancement of sensitisation by interferon is influenced by the dose of antigen and by the genotype of the mice that are sensitised.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    De Maeyer, E., De Maeyer-Guignard, J. & Vandeputte, M. Proc. natn. Acad. Sci. U.S.A. 72, 1753–1757 (1975).

  2. 2

    De Maeyer, E. J. infect. Dis. 133, A63–A65 (1976).

  3. 3

    De Maeyer-Guignard, J., Cachard, A. & De Maeyer, E. Science 190, 574–576 (1975).

  4. 4

    Gresser, I., De Maeyer-Guignard, J., Tovey, M. G. & De Maeyer, E. Proc. natn. Acad. Sci U.S.A. 76, 5308–5312 (1979).

  5. 5

    Lagrange, P. H., Mackannes, G. B. & Miller, T. E. J. exp. Med. 139, 528–542 (1974).

  6. 6

    Oie, H. K., Gazdar, A. F., Buckler, C. E. & Baron, S. J. gen. Virol. 17, 107–109 (1972).

  7. 7

    Stewart II, W. E., Gosser, L. B. & Lockart, R. Z. Jr J. Virol. 7, 792–801 (1971).

  8. 8

    De Maeyer-Guignard, J. & De Maeyer, E. C. r. hebd. Seanc. Acad. Sci., Paris 283, 709–711 (1976).

  9. 9

    De Maeyer-Guignard, J., Thang, M. N. & De Maeyer, E. Proc. natn. Acad. Sci. U.S.A. 74, 3787–3790 (1977).

  10. 10

    De Maeyer-Guignard, J., Tovey, M. G., Gresser, I. & De Maeyer, E. Nature 271, 622–625 (1978).

  11. 11

    Gisler, R. H., Lindahl, P. & Gresser, I. J. Immun. 113, 438–444 (1974).

  12. 12

    De Maeyer, E. & De Maeyer-Guignard, J. J. Virol. 3, 506–512 (1969).

  13. 13

    De Maeyer, E., De Maeyer-Guignard, J., Hall, W. T. & Bailey, D. W. J. gen Virol. 23, 209–211 (1974).

  14. 14

    Tan, Y. H., Tischfield, J. & Ruddle, F. H. J. exp. Med. 137, 317–330 (1973).

  15. 15

    Tan, Y. H. Natvre 260, 141–143 (1976).

  16. 16

    Epstein, L. B. & Epstein, C. J. J. infect. Dis. 133, A56–A62 (1976).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.